In fact, Carter et al. [144] demonstrated that BCR-ABL and its downstream effector mitogen-activated protein kinase (MAPK) could target survivin expression at both RNA and protein levels in cells derived from a patient with CML-BP Ph chromosome positive. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.